Oncology

Back to articles

Pembrolizumab: An effective option for patients with some types of non–small cell lung cancer

KEY POINT

A recent study found that pembrolizumab (Keytruda—Merck Sharpe & Dohme) prolongs overall survival (OS) in patients with a specific type (PD-L1 positive) advanced non–small cell lung cancer (NSCLC). By releasing constraints on the immune system, this programmed death (PD) checkpoint inhibitor may allow patients’ immune systems to attack NSCLC.